Here is identification of drug products according to Q6A. You do not need to study degradaion products but you have to make identification according to standard and a closely related compond (maybe another peptide in your case) should be shown in your chromatogram (like many identification methods in Ph. Eu. Besides working on a PDA detector and showing the comparison of standard and sample spectra will be a plus.
Identification testing should establish the identity of the new drug substance(s) in the new drug product and should be able to discriminate between compounds of closely related structure which are likely to be present. Identity tests should be specific for the new drug substance, e.g., infrared spectroscopy. Identification solely by a single chromatographic retention time, for example, is not regarded as being specific. However, the use of two chromatographic procedures, where the separation is based on different principles, or combination of tests into a single procedure, such as HPLC/UV diode array, HPLC/MS, or GC/MS, is generally acceptable.